BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Arthur Klausner to speak at FundingPost's early-stage VC breakfast in New York City on May 18
News | 05. 18. 2006
